Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 16, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
November 15, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – November 15, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 06, 2023 14:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 03, 2023 15:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
October 30, 2023 03:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial
October 25, 2023 02:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
October 20, 2023 14:01 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
October 20, 2023 14:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
October 10, 2023 14:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
October 03, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 3, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...